Ovid Therapeutics (OVID) Other financing activities (2017 - 2026)
Ovid Therapeutics (OVID) posted Other financing activities of $59.8 million for Q1 2026, down 20.36% on a QoQ basis from $75.1 million in Q4 2025, and up 459923.08% year-over-year from N/an in Q1 2025.
Ovid Therapeutics (OVID) Other financing activities (2017 - 2026) Analysis & Trends
Ovid Therapeutics' Other financing activities history runs 10 years deep, the most recent figure standing at $59.8 million for Q1 2026.
- Quarterly Other financing activities rose 459923.08% year-over-year to $59.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134.9 million (up 62846.98% YoY) and the FY2025 annual result came in at $75.1 million, changed N/A from the prior year.
- Other financing activities was $59.8 million for Q1 2026 at Ovid Therapeutics, down from $75.1 million in the prior quarter.
- Across five years, Other financing activities topped out at $75.1 million in Q4 2025 and bottomed at -$622000.0 in Q4 2024.
- A 5-year average of $8.5 million and a median of $74314.5 in 2022 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2024 — Other financing activities sank 1984.85% — and 2026, when it soared 459923.08%.
- Ovid Therapeutics' Other financing activities stood at -$43599.0 in 2022, then jumped by 175.69% to $33000.0 in 2023, then sank by 1984.85% to -$622000.0 in 2024, then jumped by 12172.03% to $75.1 million in 2025, then fell by 20.36% to $59.8 million in 2026.
- Business Quant data shows OVID's Other financing activities at $59.8 million in Q1 2026, $75.1 million in Q4 2025, and $15000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.80 Mn |
| Mar 31, 2026 | 59.80 Mn |
| Dec 31, 2025 | 75.09 Mn |
| Dec 31, 2025 | 75.09 Mn |
| Sep 30, 2025 | 15,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Dec 31, 2024 | -622,000.00 |
| Dec 31, 2024 | -622,000.00 |
| Sep 30, 2024 | 38,000.00 |
| Sep 30, 2024 | 38,000.00 |
| Jun 30, 2024 | 356,000.00 |
| Jun 30, 2024 | 356,000.00 |
| Mar 31, 2024 | 228,000.00 |
| Mar 31, 2024 | 228,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Sep 30, 2023 | 224,000.00 |
| Sep 30, 2023 | 224,000.00 |